News
Article
Top 5 Most-Read Vaccine Content of 2023
Author(s):
The most-viewed vaccine content for this year encompassed cost, efficacy, and skepticism surrounding vaccination, particularly targeting COVID-19.
In 2023, our top 5 most read and viewed content in vaccines covered cost, efficacy and safety, and consumer perspectives, especially in COVID-19 vaccines.
Here are the top 5 most-viewed vaccine content items of 2023.
5. Dr Amy Crawford-Faucher Discusses the Future of Vaccination for COVID-19
In this interview, Amy Crawford-Faucher, MD, vice chair of the Primary Care Institute and Department of Family Medicine at Allegheny Health Network, discussed recent World Health Organization research indicating long-lasting protection against COVID-19 for individuals who have been both vaccinated and previously infected up to 12 months after infection. Crawford-Faucher suggested that if this evidence continues to hold, maintaining high COVID-19 vaccination and booster rates could contribute to achieving a level of herd immunity that makes COVID-19 resemble the flu.
4. COVID-19 Vaccine Not Associated With Adverse Outcomes in Pregnant Women
A study found that COVID-19 vaccination during pregnancy was not associated with adverse outcomes for both neonates and mothers. The study, based on 43 observational studies involving 599,956 pregnant individuals, revealed that COVID-19 vaccination during pregnancy was associated with a reduced risk of stillbirth or neonatal death. The analysis also found no significant associations between COVID-19 vaccination during pregnancy and adverse outcomes such as fetal or neonatal congenital anomalies, preterm birth, low birth weight, neonatal intensive care unit admission, cesarean delivery, or postpartum hemorrhage.
3. COVID-19, Flu, and RSV Vaccine Skepticism Still an Issue Among Many Americans
Vaccine hesitancy remains a concern despite the efficacy of vaccines, with only 40% of US adults planning to get vaccinated against COVID-19, according to a National Foundation for Infectious Diseases poll. The survey also revealed that 43% of adults do not plan to or are unsure if they will get the flu vaccine, and only 40% of adults aged 60 or older plan on getting vaccinated for respiratory syncytial virus (RSV).
2. Biden Administration Releases Drug Rebate List, Promotes End of Vaccine Cost Sharing
The Biden administration released a list of 27 Medicare Part B drugs subject to rebates under the Inflation Reduction Act due to price increases exceeding inflation rates. Notable drugs on the list include chimeric antigen recptor T-cell therapies axicabtagene ciloleucel (Yescarta) and brexucabtagene autoleucel (Tecartus), as well as adalimumab (Humira) and triamcinolone acetonide injectable suspension (Xipere). Additionally, the administration highlighted the impact of the law on removing cost sharing for vaccines, stating that if the policy had been in effect in 2021, 3.4 million Medicare beneficiaries would have collectively saved $70 per beneficiary receiving vaccines under Part D.
1. 4-Dose COVID-19 Vaccine Less Effective Beyond 90 Days
A study found that vaccine effectiveness against SARS-CoV-2 infection declined after the 90-day mark post vaccination. However, the mRNA-1273 vaccine remained effective in preventing hospitalizations. The study focused on omicron subvariants, including BA.1, BA.2, BA.2.12.1, BA.4, and BA.5, and assessed the effectiveness of the mRNA-1273 vaccine against infection and hospitalization. The results indicated that the vaccine's effectiveness against infection decreased over time but remained robust in preventing hospitalizations for COVID-19.
